New eye drug shows promise in early safety trial for blinding disease
NCT ID NCT05643118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug might help improve vision.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
California Retina Consultants
Santa Maria, California, 93434, United States
-
Ophthalmic Consultants of the Capital Region
Troy, New York, 12180, United States
-
Texas Retina Consultants
Bellaire, Texas, 77401, United States
-
The Retina Institute
St Louis, Missouri, 63128, United States
-
University Retina
Oak Forest, Illinois, 60452, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection save vision in wet AMD?
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- New eye drug aims to save sight in wet AMD
- Withdrawn study sought better way to time eye injections